M
Maria Czarina Acelajado
Researcher at University of Alabama at Birmingham
Publications - 18
Citations - 606
Maria Czarina Acelajado is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Hyperaldosteronism. The author has an hindex of 10, co-authored 18 publications receiving 533 citations. Previous affiliations of Maria Czarina Acelajado include Medical University of South Carolina & Philippine General Hospital.
Papers
More filters
Journal ArticleDOI
Refractory Hypertension: Definition, Prevalence, and Patient Characteristics
Maria Czarina Acelajado,Roberto Pisoni,Tanja Dudenbostel,Louis J. Dell'Italia,Falynn Cartmill,Bin Zhang,Stacey S. Cofield,Suzanne Oparil,David A. Calhoun +8 more
TL;DR: In this article, patients with refractory hypertension were defined as those who remained uncontrolled after ≥3 visits to a hypertension clinic within a minimum 6-month follow-up period.
Journal ArticleDOI
Refractory Hypertension Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure
Tanja Dudenbostel,Maria Czarina Acelajado,Roberto Pisoni,Peng Li,Suzanne Oparil,David A. Calhoun +5 more
TL;DR: Evidence of heightened sympathetic tone as indicated by 24-hour urinary normetanephrine levels, clinic and ambulatory heart rate, HR variability, arterial stiffness as indexed by pulse wave velocity, and systemic vascular resistance compared with patients with controlled resistant hypertension is found.
Journal ArticleDOI
Treatment of Resistant and Refractory Hypertension.
TL;DR: Refractory hypertension is defined as uncontrolled blood pressure despite use of ≥5 antihypertensive agents of different classes, including a long-acting thiazide-like diuretic and an MR (mineralocorticoid receptor) antagonist, at maximal or maximally tolerated doses.
Journal ArticleDOI
Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment.
TL;DR: Mineralocorticoid receptor antagonists are formidable add-on agents to the antihypertensive regimen, usually as a fourth drug, and are effective in reducing BP even in patients without biochemical evidence of aldosterone excess.
Journal ArticleDOI
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease
Roberto Pisoni,Maria Czarina Acelajado,F R Cartmill,Tanja Dudenbostel,Louis J. Dell'Italia,Stacey S. Cofield,Suzanne Oparil,David A. Calhoun +7 more
TL;DR: MRAs significantly reduced blood pressure in subjects with resistant hypertension associated with stage 3 CKD, although close biochemical monitoring is recommended because of an increased risk of hyperkalemia and worsening of renal function.